Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ITK | Q08881 | 2/20 | 0.31 |
| ▸ | INSR | P06213 | 1/20 | 0.31 |
| ▸ | HTR5A | P47898 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4664618 | 0.83 | KMT2A (0.35) | DHFRKMT2AHSD11B1HPGDRAB9A | |
| SCHEMBL4964916 | 0.79 | RAB9A (0.34) | KMT2AHSD11B1HPGDRAB9AGAA | |
| SCHEMBL4664575 | 0.78 | KMT2A (0.41) | KMT2AHPGDRAB9AGAAALDH1A1 | |
| SCHEMBL4964193 | 0.77 | KMT2A (0.37) | KMT2AALDH1A1POLB | |
| SCHEMBL4963473 | 0.74 | SMN1; SMN2 (0.41) | KMT2AHPGDRAB9AALDH1A1NPC1 | |
| SCHEMBL4964535 | 0.73 | PDK1 (0.35) | HSD11B1RAB9AGAAALDH1A1NPC1 | |
| SCHEMBL4963781 | 0.72 | CTNNB1 (0.35) | KMT2AHPGDRAB9AGAAALDH1A1 | |
| SCHEMBL4664854 | 0.71 | KMT2A (0.34) | DHFRKMT2AHSD11B1HPGDRAB9A | |
| SCHEMBL4663226 | 0.71 | KMT2A (0.33) | DHFRKMT2AHSD11B1HPGDRAB9A | |
| SCHEMBL4965054 | 0.71 | HCRTR1 (0.32) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113963-A1 | Cyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2008-05-15 | — | — | US | disclosed |
| US-7307084-B2 | Cyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2007-12-11 | — | — | US | disclosed |
| US-20060194968-A1 | Cyclic benizimidazoles | ALTANA PHARMA AG (DE) | 2006-08-31 | — | — | US | disclosed |
| EP-1613626-A1 | CYCLIC BENZIMIDAZOLES | ALTANA Pharma AG (DE) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087701-A1 | CYCLIC BENZIMIDAZOLES | ALTANA PHARMA AG (DE) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194968-A1 | Cyclic benizimidazoles | VIP, SI, GIPR | DHFR 619/4885KMT2A 3220/4885HSD11B1 967/4885 |
| US-20080113963-A1 | Cyclic benzimidazoles | VIP, GIPR, SI | DHFR 3289/4885KMT2A 4735/4885HSD11B1 2384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.